Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAGINE-2 brodalumab versus placebo and ustekinumab in moderate to severe plaque psoriasis
NL-OMON41423Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brodalumab in plaque psoriasis and psoriasis (4 arms), sponsored by Amgen. Started Jan 2013; status: active, not recruiting.
02
Drugs
brodalumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on NL-OMON41423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41423.